Replimune : Corporate Presentation May 2024

Igniting a Systemic Immune Response to Cancer

Corporate Presentation

May 2024

Safe Harbor

Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the advancement, timing and sufficiency of our clinical trials, patient enrollments in our existing and planned clinical trials and the timing thereof, the results of our clinical trials, the timing and release of our clinical data, statements regarding our expectations about our cash runway, our goals to develop and commercialize our product candidates, our expectations regarding the size of the patient populations for our product candidates if approved for commercial use and other statements identified by words such as "could," "expects," "intends," "may," "plans," "potential," "should," "will," "would," or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive pressures, our ability to identify additional product candidates, political and global macro factors including the impact of global pandemics and related public health issues, the ongoing military conflicts between Russia-Ukraine and Israel-Hamas and the impact on the global economy and related governmental imposed sanctions, and other risks as may be detailed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and other reports we file with the Securities and Exchange Commission. Our actual results could differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

© 2024 Replimune Group Inc.

2

Industry Leader in Oncolytic Immunotherapy

Establishing a Broad

Skin Cancer Franchise

Clinical activity demonstrated across multiple skin cancers and settings

• IGNYTE primary analysis and BLA submission in anti-PD1 failed melanoma on track for RP1 in 2H 2024
• IGNYTE-3confirmatory phase 3 study design in anti-PD1 failed melanoma agreed on with FDA; planned to start prior to BLA submission
• ARTACUS clinical trial of RP1 as monotherapy in solid organ transplant patients shows strong response rates
• CERPASS study continuing to allow time- based endpoints to mature

Focused on Rare Cancers

Powerful activity both as monotherapy and in combination with nivolumab

• Compelling data in uveal melanoma
• Pivotal study in metastatic uveal melanoma being planned
• Clinical activity seen in other rare tumors, including:
• • Sarcomas (e.g., chordoma)
  • Rare head & neck (e.g., mucoepidermoid)
• On path to build rare cancer franchise

Posi9oned to Bring our Oncoly9c

Immunotherapies to Market

Industry leading experience and pipeline in oncolytic immunotherapy

• All programs wholly owned
• Potential to deliver substantial commercial revenues beginning in late 2025
• Strong financial position with cash of $466.4M as of 31 December 2023
• Cash runway into 2H 2026

© 2024 Replimune Group Inc.

3

Oncolytic Immunotherapy is Intended to Activate a Powerful and Durable Systemic Anti-Tumor Response

Attenuated potent new clinical isolate of HSV-1 modified to express a fusogenic glycoprotein and immune stimulating proteins

Intact host antiviral response: Normal tissue remains undamaged

Healthy tissue

Injected tumor

Oncolytic
immunotherapy	M E C H A N I S M
Dysregulated host antiviral	1
response allows robust virus
replication and tumor lysis

Tumor tissue

Immune response

M E C H A N I S M		Dendritic cell
2		T cell
Tumor cell death and	Enhanced T cell
	release of tumor antigens	priming and activation
Release	Local	T cell infiltration and killing of
of virus progeny	Inflammation	distant, uninjected tumors
Infection of more	Altering of tumor	Generating a strong and
tumor cells	microenvironment	durable systemic anti-
		tumor immune response

Injected

tumor

Distant tumors

Bommareddy PK et al AJCD. 2016

© 2024 Replimune Group Inc.

4

RPx Platform Addresses a Range of Tumor Types

Intending to Optimize Clinical Outcomes

Payloads	GALV-GPR-,GM-CSF	GALV-GPR-,anti-CTLA-4,GM-CSF
Target	Immunologically responsive tumor types, including anti-	Less immunologically responsive tumor types
PD1 failed
Intended indication(s)	Skin cancers (CSCC inc. SOT*, anti-PD1 failed melanoma,	Rare cancers and neo adjuvant ; uveal melanoma
anti-PD1 failed CSCC, other NMSCs, etc)	registration study planned
Clinical activity in anti-PD1 failed
patients demonstrated
Good tolerability and Safety
profile demonstrated
Injection location	Superficial, nodal & visceral	Superficial, nodal & visceral
Systemic activity	Clear systemic effects seen in responding patients (un-injected tumor responses,
responses are generally highly durable)
Other design considerations	Designed for more I-O sensitive tumor types with excellent	Increased I-O systemic activity, also with excellent
safety profile alone & in combination	safety profile alone & in combination

*SOT=solid organ transplant

© 2024 Replimune Group Inc.

5

Pipeline

	Clinical trials & indication	IND/CTA	Phase 1/2	Phase 2	Registration-Directed	Top-line Data
	Engineered HSV backbone + GM-CSF + GALV-GP R-
			Melanoma		phase 1/2 complete
		(inc. anti-PD1 failed)		Fullyenrolled;ph 1/2 complete
	IGNYTE*		NMSC
	+ nivolumab	(inc. anti-PD1 failed)
		MSI-H cancers
		(anti-PD1 failed)
	ARTACUS	Skin cancers
	RP1 monotherapy	organ transplant
	IGNYTE-3		Melanoma		Confirmatory phase 3 trial
	+ nivolumab	(anti-PD1 failed)
	CERPASS#		CSCC
	+ cemiplimab
	Engineered HSV backbone + GM-CSF + GALV-GP R- + anti-CTLA-4
	Signal-finding*	Solid tumors
	+/- nivolumab
	2L HCC^		HCC
	+ bevacizumab/atezolizumab
	Metastatic		Planning underway
	Uveal Melanoma Uveal Melanoma
* Under a clinical trial collaboration & supply agreement with BMS for the supply of nivolumab - full commercial rights retained by Replimune			6 6
# Under a clinical trial collaboration agreement with Regeneron, includes certain sharing of clinical trial costs - full commercial rights retained by Replimune
^ Under clinical trial collaboration & supply agreement with Roche for atezolizumab & bevacizumab supply - full commercial rights retained by Replimune

RP1: Establishing a Broad Skin

Cancer Franchise

© 2024 Replimune Group Inc.

7

IGNYTE Clinical Trial

© 2024 Replimune Group Inc.

8

High Unmet Need in Anti-PD1 Failed Melanoma Creates a Significant Potential RP1 Opportunity

5TH

Most common cancer

in the US1

~98,000

Incidence in the US1

~8,000

Unmet needs remain for anti-PD1

failed patients

40-65% of all metastatic melanoma are

refractory to initial anti-PD1 therapy2

6-7% expected response to anti-PD1 therapy following confirmed progression on single agent anti-PD13,4

~30% response with lifileucel (Amtagvi ); AE profile and logistical hurdles potentially limit

Other options for patients who have not already received anti-CTLA-4:

ipilimumab, ipi +nivo or Opdualag

~12% expected response for Opdualag5*

10%-30% response for ipilimumab or ipi+nivo

with high toxicity6-8

Other options for patients who have received anti-CTLA-4:

Annual deaths

in the US1

broad utility

™

~12% expected response for Opdualag5*

1National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2023 Estimates. 2Global Burden of Disease Cancer Collaboration JAMA Oncol 2019 (12; 3Ribas et al Lancet Oncology 2018 (19); 4Hodi et al JCO 2016 (34) ;5Ascierto P, JCO 2023 (RELATIVITY-020),6Pires da Silva I, et al. Lancet Oncol. 2021;22(6):836-847,7Olson DJ, et al. J Clin Oncol. 2021;39(24):2647-2655.;8Vanderwalde AM, et al. Presented at AACR 2022. New Orleans *Study (RELATIVITY-020) included multiple parts; presented data is from part D2, which allowed for failure of multiple lines of immunotherapy including ipi-nivo

© 2024 Replimune Group Inc.

9

IGNYTE: Phase 2 Study Design

Anti-PD1 Failed Cutaneous Melanoma Cohort; Registration-directed

Tumor response assessment

Radiographic imaging (CT) at baseline and every 8 weeks from first dose and every 12 weeks after confirmation of response

Screening	28 days	First Dose	2 Weeks	RP1+Opdivo	2 Weeks	Opdivo	2 Weeks	Opdivo
	RP11X10^6		1X10^7, 240 mg		240 mg		480 mg (Q4W)
									100 Day
Anti-PD1 Failed Cutaneous									Safety
Melanoma (N=140)		Cycle 1		Cycle 2-8		Cycle 9	Cycles 10-30*	Follow-Up

Primary Objectives

• To assess the safety and tolerability of RP1 in combination with nivolumab
• To assess the efficacy of RP1 in combination with nivolumab as determined by ORR using modified RECIST 1.1 criteria

3-yearfollow-up post last patient enrolled

Key Eligibility

Advanced or metastatic non-neurological solid tumors without treatment options; at least 1 measurable and injectable lesion (≥ 1cm LD); adequate organ function; no prior treatment with oncolytic therapy. ECOG performance status (PS) 0-1.

Secondary Objectives

To assess the efficacy of RP1 in combination with nivolumab as determined by DOR, CR rate, DCR, PFS, and 1-year and 2-year OS

Note: Dosing with Opdivo begins at Dose 2 of RP1 (C2D15) *Option to reinitiate RP1 for 8 cycles if criteria are met

Data shown is a snapshot from the ongoing study, with a data cut off date of 6th Nov 2023

Criteria for CPI-failed:

At least 8 weeks of prior anti-PD1, confirmed progression while on anti-PD1, anti- PD1 must be the last therapy before the clinical trial. Patients on prior adjuvant therapy must have progressed while onprior adjuvant treatment (confirmed by biopsy).

© 2024 Replimune Group Inc.

10